About AusperBio
AusperBio is a Healthcare company based in San Mateo (United States) founded in 2019 by Guofeng Cheng and Chris Yang. It operates as a therapies for chronic hepatitis B and infectious diseases are developed. AusperBio has raised $343 million across 5 funding rounds from investors including Qiming Venture Partners, Hankang Capital and Sherpa Capital. Its chief executive is Guofeng Cheng. AusperBio offers products and services including Med-Oligo ASO Platform. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Eiger BioPharmaceuticals, Aligos Therapeutics, Ascentage Pharma, Bluejay Therapeutics and Presidio Pharmaceuticals and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
AusperBio was founded in 2019 in San Mateo, United States, within the biotechnology sector. Focus is placed on developing treatments for chronic hepatitis B and other major infectious diseases. A pipeline of oligonucleotide therapeutics is maintained, featuring AHB-137, which utilizes conjugation technology for targeted delivery. This approach integrates DNA replication inhibitors, HBsAg inhibitors, and immunomodulators to address disease mechanisms. Operations emphasize research and therapeutic innovation in infectious disease management.
- Headquarters San Mateo, United States
- Founders Guofeng Cheng, Chris Yang
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ausperbio.com
- Social LinkedIn
- Total Equity Funding$343M (USD)
in 5 rounds
- Latest Funding Round$120M (USD), Series C
Aug 2026
- InvestorsQiming Venture Partners
& 9 more
Products & Services of AusperBio
AusperBio offers a comprehensive portfolio of products and services, including Med-Oligo ASO Platform.
Platform for targeted delivery of ASO therapeutics to treat various diseases.
Funding Insights of AusperBio
AusperBio has successfully raised a total of $343M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $120 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $343M
- Total Rounds 5
- Last Round Series C — $120M
- First Round $37M
(Jul 2024)
- Investors Count 10
All 5 funding rounds of AusperBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $120M | Series C | – | – | |
| Sep 2025 | $63M | Series B | – | Qiming Venture Partners | |
| May 2025 | $50M | Series B | – | – | |
| Dec 2024 | $73M | Series B | – | Hankang Capital | |
| Jul 2024 | $37M | Series A | – | InnoPinnacle Fund |
10 investors in total: 10 institutional.
Investors in AusperBio
AusperBio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, Hankang Capital and Sherpa Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | hankangcapital.com | - | |
Private equity investments are directed toward opportunities in Spain. | – | sherpacapital.es | Madrid, Spain | |
Private equity and private debt firm focused on multiple sectors | – | cdhfund.com | Kowloon, China | |
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
BioVenture is focused on early and growth-stage healthcare investments. | 2013 | bioventure.com.cn | Suzhou, China | |
Growth capital investments are managed by this private equity fund. | – | gcfunds.com | Beijing, China | |
- | – | sherpahp.com | - | |
- | – | hankangcapital.tcc.mode | - | |
- | – | innopinnaclefund.tcc.mode | - | |
- | – | racap.com | - |
Investor details for AusperBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AusperBio
2 people are tracked at AusperBio (2 in leadership).
| Name | Role | Group |
|---|---|---|
Guofeng Cheng | Co-Founder & CEO | Leadership |
Chris Yang | Co-Founder & CSO | Leadership |
Complete people profiles for AusperBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AusperBio
3 dated milestones of AusperBio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded AusperBio is founded.
- Funding First funding round of $37.0M.
- Funding Latest funding round, Series C, of $120.0M.
Competitors of AusperBio
AusperBio has 9 listed competitors in our database, 9 of them funded. They include Eiger BioPharmaceuticals, Aligos Therapeutics, Ascentage Pharma, Bluejay Therapeutics and Presidio Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| eigerbio.com | 2000 | San Carlos, United States | $8.9M | 56 | Developer of antiviral agents against targets in the treatment of hepatitis | |
| aligos.com | 2018 | San Francisco, United States | $225M | 70 | Developer of therapies to treat hepatologic diseases and viral infections | |
| ascentagepharma.com | 2009 | Hong Kong, China | $237.5M | – | Small molecule drugs for cancer treatment are developed. | |
| bluejaytx.com | 2019 | San Francisco, United States | $243M | 3 | Therapeutics for infectious diseases treatment are developed. | |
| presidiopharma.com | 2006 | San Francisco, United States | $91.93M | – | Small-molecule antiviral therapeutics for hepatitis C are developed. | |
| finchtherapeutics.com | 2004 | Somerville, United States | $184M | – | Microbiome-based therapies are developed via human-first discovery platform. | |
| xtyw.com.cn | 2000 | Xi An, China | $14.61M | – | Drugs for treating infectious and liver diseases are developed. | |
| achillion.com | 1998 | New Haven, United States | $41M | 2,372 | Treatments for Hepatitis C and complement-mediated diseases are developed. | |
| carogencorp.com | 2012 | Hamden, United States | $2.23M | – | Recombinant protein nanoparticle vaccines for hepatitis B are developed. |
Detailed competitors of AusperBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as AusperBio (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ausperbio
Complete news archive for AusperBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AusperBio
AusperBio was founded in 2019 and raised its 1st funding round 5 years after it was founded.
AusperBio is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Guofeng Cheng is the current CEO of AusperBio. They have also founded this company.
AusperBio is a funded company, having raised a total of $343M across 5 funding rounds to date. The company's 1st funding round was a Series A of $37M, raised on Jul 2024.
AusperBio was founded in 2019 in San Mateo, United States, within the biotechnology sector. Focus is placed on developing treatments for chronic hepatitis B and other major infectious diseases. A pipeline of oligonucleotide therapeutics is maintained, featuring AHB-137, which utilizes conjugation technology for targeted delivery. This approach integrates DNA replication inhibitors, HBsAg inhibitors, and immunomodulators to address disease mechanisms. Operations emphasize research and therapeutic innovation in infectious disease management.
AusperBio's top competitors include Eiger BioPharmaceuticals, Finch Therapeutics and Aligos Therapeutics.
AusperBio offers Med-Oligo ASO Platform.
AusperBio has 10 investors. Key investors include Qiming Venture Partners, Hankang Capital, Sherpa Capital, CDH, and BioVenture.